EIQ FDA NSE letter delays heart failure solution timeline
EIQ said an FDA NSE letter for its heart failure solution delayed progress but did not derail it. Management is pursuing multiple regulatory pathways and maintaining high FDA engagement, supported by financial strength and an R&D pipeline.
A recent FDA NSE letter for the heart failure solution has delayed but not derailed progress, with management actively pursuing multiple regulatory pathways and maintaining high engagement with the FDA. The company said financial strength, ongoing commercialization of other products and a robust R&D pipeline continue to support its position.